Your browser doesn't support javascript.
loading
Novel monoclonal antibodies showing broad neutralizing activity for SARS-CoV-2 variants including Omicrons BA.5 and BA.2.75
Hanako Ishimaru; Mitsuhiro Nishimura; Lidya Handayani Tjan; Silvia Sutandhio; Maria Istiqomah Marini; Gema Barlian Effendi; Hideki Shigematsu; Koji Kato; Natsumi Hasegawa; Kaito Aoki; Yukiya Kurahashi; Koichi Furukawa; Mai Shinohara; Tomoka Nakamura; Jun Arii; Tatsuya Nagno; Sachiko Nakamura; Shigeru Sano; Sachiyo Iwata; Yasuko Mori.
Afiliação
  • Hanako Ishimaru; Kobe University Graduate School of Medicine School of Medicine:
  • Mitsuhiro Nishimura; Kobe University Graduate School of Medicine School of Medicine:
  • Lidya Handayani Tjan; Kobe university Graduate School of Medicine School of Medicine:
  • Silvia Sutandhio; Kobe University Graduate School of Medicine School of Medicine:
  • Maria Istiqomah Marini; Kobe University Graduate School of Medicine School of Medicine:
  • Gema Barlian Effendi; Kobe University Graduate School of Medicine School of Medicine:
  • Hideki Shigematsu; Japan Synchrotron Radiation Research Institute SPring-8
  • Koji Kato; Japan Synchrotron Radiation Research Institute SPring-8
  • Natsumi Hasegawa; Kobe University Graduate School of Medicine School of Medicine:
  • Kaito Aoki; Kobe University Graduate School of Medicine School of Medicine:
  • Yukiya Kurahashi; Kobe University Graduate School of Medicine School of Medicine:
  • Koichi Furukawa; Kobe University Graduate School of Medicine School of Medicine:
  • Mai Shinohara; Kobe university Graduate School of Medicine School of Medicine:
  • Tomoka Nakamura; kobe University Graduate School of Medicine School of Medicine:
  • Jun Arii; Kobe University Graduate School of Medicine School of Medicine:
  • Tatsuya Nagno; Kobe University Graduate School of Medicine School of Medicine:
  • Sachiko Nakamura; Hyogo Prefectural Kakogawa Medical Center
  • Shigeru Sano; Hyogo Prefectural Kakogawa Medical Center
  • Sachiyo Iwata; Hyogo Prefectural Kakogawa Medical Center
  • Yasuko Mori; Kobe University Graduate School of Medicine School of Medicine:
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-506305
ABSTRACT
We identified novel neutralizing monoclonal antibodies against SARS-CoV-2 variants (including Omicron) from individuals received two doses of mRNA vaccination after they had been infected with wildtype. We named them MO1, MO2 and MO3. MO1 shows high neutralizing activity against authentic variants D614G, Delta, BA.1, BA.1.1, BA.2, and BA.2.75 and BA.5. Our findings confirm that the wildtype-derived vaccination can induce neutralizing antibodies that recognize the epitopes conserved among the SARS-CoV-2 variants (including BA.5 and BA.2.75). The monoclonal antibodies obtained herein could serve as novel prophylaxis and therapeutics against not only current SARS-CoV-2 viruses but also future variants that may arise.
Licença
cc_no
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
...